James Love's blog
On December 14, 2010, Life Technologies Corporation, which among other things owns Ion Torrent, which sells the Ion Personal Genome Machine sequencer, announced seven new medical innovation prizes. The first three prizes are related to improvements in the Ion semiconcudtor sequencing products. Each of the three sequencer prizes is funded at $1 million, and will be awarded to contestants that can achieve the following goals:
- produce twice as much sequence data,
NSF, Gates Foundation policies on sharing data and intellectual property in agricultural basic research grant program (BREAD)Submitted by James Love on 5. January 2011 - 8:30
The US based National Science Foundation (NSF) and the Bill and Melinda Gates Foundation are collaborating on a program called Basic Research to Enable Agricultural Development (BREAD). A May 12, 2010 NSF announcement about the program is available here.
Cancer: Annual deaths compared to new cases in 2004, for 16 types of cancer and 4 World Bank income groupsSubmitted by James Love on 21. December 2010 - 10:21
The following table compares the annual deaths from cancer, to the annual incidence of the disease, broken down by cancer type and income group. The data in the table is annual deaths divided by annual incidence, show as a ratio.
For several types of cancer, there is not much difference in the reported ratios, between different income groups. For other types of cancer, the differences are large, and in favor of patients living in higher income countries. Cancer types with the largest disparities by income include the following:
- Mouth and oropharynx cancers
Ratio of year 2000 breast cancer deaths to new breast cancer patients in Europe, by country and country incomeSubmitted by James Love on 21. December 2010 - 8:37
The following graph presents the year 2000 raw mortality rate of breast cancer patients in 36 European Countries. The graph compares the ratio of breast cancer deaths to the annual incidence of breast cancer, to the per capita incomes in those countries, all based upon year 2000 data.
USTR has issued a request for comments on ACTA. The deadline for submissions is February 15, 2011. The notice gives very little guidance regarding the issues the USTR would like addressed in the comments.
[Billing Code 3190-W1-P]
Office of the United States Trade Representative
Anti-Counterfeiting Trade Agreement: Request for Comments from the Public
Agency: Office of the United States Trade Representative
Action: Request for written submissions from the public
Today USTR provided some additional insight into negotiations of a regional, Asia-Pacific trade agreement, known as the Trans-Pacific Partnership (TPP) Agreement. The USTR web page on the TPP negotiations is http://www.ustr.gov/tpp. At present, the TPP negotiators include Australia, Brunei Darussalam, Chile, New Zealand, Peru, Singapore and Vietnam. Japan and Canada have expressed interest in joining the negotiations, and USTR clearly would like to design an agreement that will be open to other countries. Our discussions focused on the intellectual property chapter in the agreement.
13 December 2010
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998
What is Herceptin? How does it work?
For background on the Fabrazyme case, see: http://www.keionline.org/fabrazyme
The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at firstname.lastname@example.org if your organization would like to submit an statement.
Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)
Today I am attending a meeting at the European Parliament on new models of innovation for medical technologies. The event was organized by three MEPs, Thijs Berman, Eva Joly and Carl Schlyter, in collaboration with the European Parliament Working Group on Innovation, Access to Medicines and Poverity-Related Diseaes, and several consumer rights, public health and development NGOs (TACD, Health Action International, KEI, Oxfam and IQsensato).
Non-responsive letter from David Kappos of USPTO to Senators Sanders and Brown regarding ACTA consistency with US lawSubmitted by James Love on 17. November 2010 - 12:56
In a October 19, 2010, Senators Bernard Sanders (I-VT) and Sherrod Brown (D-OH) wrote to David Kappos, the Director of the USPTO, asking for an assessment of conflicts between the October 2010 ACTA text, and U.S. law. (attached here).
|Undersecretary of Commerce for
Intellectual Property, David Kappos
From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500
This note cites several areas where US law is plainly inconsistent with
In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
Some examples of inconsistencies between ACTA and US law
Sometime very early Saturday morning, SCCR 21 ended with these conclusions.
This was our 400 word statement at the WIPO SCCR 21.
Statement of KEI at WIPO SCCR 21, November 11, 2010
There should be a compelling rationale for creating new global norms for copyrights.
KEI opposes work on a new broadcasting treaty, and supports work on performers treaty.
KEI supports work at the SCCR on new possible norms for copyright limitations and exceptions, particularly as regards to access to knowledge, and uses of new technologies.